Does Low Back Position Matters in Manual Therapy Treatment

Sponsor
University of Jaén (Other)
Overall Status
Completed
CT.gov ID
NCT04664348
Collaborator
(none)
53
1
2
4.7
11.4

Study Details

Study Description

Brief Summary

The study will be carried out at the Faculty of Nursing and Physiotherapy of the University of Alcalá. The study has been approved by the Animal Research and Experimentation Ethics Committee of the University of Alcalá. A total of 46 subjects of legal age with non-specific chronic low back pain will be selected and randomized into two interventions.

The first group will receive lumbar posteroanterior mobilizations with the lumbar spine in extension and the second group will receive lumbar mobilizations with neutral position of the spine. Both groups will also receive a home exercise program for the lumbar spine.

The total duration of the treatments will be 6 weeks, with pre-treatment, at 3 weeks of the treatment, post-treatment evaluations at 6 weeks, with a follow-up after 1 month and with a follow-up after 3 months.

The objective will be to evaluate which of the two interventions is more effective in addressing disability variables (main variable), pressure pain threshold, pain location, pain intensity, quality of life, quality of sleep, depression and kinesiophobia.

Condition or Disease Intervention/Treatment Phase
  • Other: Posteroanterior mobilization (neutral)
  • Other: Posteroanterior mobilization (extension)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
53 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Is the Positioning of the Lumbar Spine Relevant to the Manual Treatment of the Chronic Low Back Pain
Actual Study Start Date :
Dec 9, 2020
Actual Primary Completion Date :
Jan 31, 2021
Actual Study Completion Date :
Apr 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental: Posteroanterior lumbar mobilization (extension of the lumbar spine)

Other: Posteroanterior mobilization (extension)
Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms. Positioning of the therapist: Stand to one side of the table at the pelvis of the patient. Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.

Experimental: Experimental: Posteroanterior lumbar mobilization (lumbar spine in neutral positioning)

Other: Posteroanterior mobilization (neutral)
Positioning of the patient: Prone position with the lumbar area uncovered. Positioning of the therapist: Stand to one side of the table at the pelvis of the patient. Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain. Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment.

Outcome Measures

Primary Outcome Measures

  1. Changes in Disability [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    measured with the Oswestry Low Back Pain Disability Questionnaire. The interpretation of the scores of this scale varies from 0% to 100%. 0% to 20%: minimal disability: The patient can cope with most living activities. 21%-40%: moderate disability 41%-60%: severe disability 61%-80%: crippled 81%-100%: These patients are either bed-bound or exaggerating their symptoms.

Secondary Outcome Measures

  1. Changes in Pressure pain threshold [Baseline, 3 weeks and 6 weeks after intervention commencement]

    measured with a Wagner brand Force Dial with a 1 cm2 rubber disc at the end of the device.

  2. Changes in Site of pain [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    measured with the body pain map

  3. Pain measured with visual analogic scale [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    A straight horizontal line of fixed length, usually 100 mm is drawn. The ends are defined as the extreme limits of the parameter to be measured (pain) orientated from the left (worst) to the right (best).

  4. Health measured with the short form health survey version II [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    It consists of 12 items from the 8 dimensions of the short form health survey 36: Physical Function, Function Social, Physical role, Emotional role, Mental health, Vitality, Body pain , General Health. For each of the 8 dimensions, the items are coded, aggregated and transformed into a scale that ranges from 0 (the worst state of health for that dimension) to 100 (the best state of health).

  5. Quality of sleep measured with the Pittsburgh Sleep Quality Index [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    In scoring the Pittsburgh Sleep Quality Index, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

  6. Depression measured with Beck's Depression Inventory [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-off scores were as follows: 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms.

  7. Kinesiophobia measured with the TAMPA scale of kinesiophobia [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    The total score ranges between 17 and 68. A high value on the TAMPA scale of kinesiophobia indicates a high degree of kinesiophobia. Cutoff score developed by Vlaeyen: score of 37 or over is considered as high scores below 37 is considered as low)

  8. Changes in Medication [Baseline, 3 weeks, 6 weeks, 1 month and 3 months after intervention commencement]

    The patient will be asked about how many days a week they have needed to take medication

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • subjects with unspecific low back pain of 3 or more months of evolution prior commencement of the intervention
Exclusion Criteria:
  • lumbar pain related to infectious diseases

  • fractures

  • oncological processes

  • women in gestation period.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Adrián Cabañas Alcalá De Henares Madrid Spain 28801

Sponsors and Collaborators

  • University of Jaén

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alexander Achalandabaso, Principal Investigator, University of Jaén
ClinicalTrials.gov Identifier:
NCT04664348
Other Study ID Numbers:
  • CEIM/HU/2020/42
First Posted:
Dec 11, 2020
Last Update Posted:
Jun 10, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2021